TMPRSS4

Summary

TMPRSS4 (transmembrane serine protease 4, HGNC:11878) is a protein-coding gene on chromosome 11q23.3, encoding Transmembrane protease serine 4 (Q9NRS4). Plasma membrane-anchored serine protease that directly induces processing of pro-uPA/PLAU into the active form through proteolytic activity.

This gene encodes a member of the serine protease family. Serine proteases are known to be involved in a variety of biological processes, whose malfunction often leads to human diseases and disorders. This gene was identified as a gene overexpressed in pancreatic carcinoma. The encoded protein is membrane bound with a N-terminal anchor sequence and a glycosylated extracellular region containing the serine protease domain. The protein has been found to promote SARS-CoV-2 entry into host cells.

Source: NCBI Gene 56649 — RefSeq curated summary.

At a glance

• Gene–disease (curated): cardiomyopathy, dilated, 2I (Moderate, GenCC) — +2 more curated relationships
• GWAS associations: 5
• Clinical variants (ClinVar): 178 total — 3 pathogenic, 1 likely-pathogenic
• GTEx eGene: eQTL in 10 tissues, sQTL in 11 (q < 0.05)
• Phenotypes (HPO): 18
• ChEMBL bioactivity: 1 clinical-phase molecule tested; no curated mechanism-of-action drug
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 0.94 (unconstrained)
• MANE Select transcript: NM_019894
• Notable: 178 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11878
Approved symbol	TMPRSS4
Name	transmembrane serine protease 4
Location	11q23.3
Locus type	gene with protein product
Status	Approved
Aliases	TMPRSS3, MT-SP2, CAP2
Ensembl gene	ENSG00000137648
Ensembl biotype	protein_coding
OMIM	606565
Entrez	56649

Gene structure

Transcript identifiers

Ensembl transcripts: 33 — 19 protein_coding, 7 retained_intron, 6 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

MANE Select: ENST00000437212

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 3, TSL 2: 7, TSL 3: 6, TSL 5: 3

ENST00000437212, ENST00000517483, ENST00000517544, ENST00000518413, ENST00000518610, ENST00000519126, ENST00000519236, ENST00000519813, ENST00000520063, ENST00000522151, ENST00000522307, ENST00000522462, ENST00000522824, ENST00000523251, ENST00000523770, ENST00000524218, ENST00000528118, ENST00000534111, ENST00000616579, ENST00000714375, ENST00000714378, ENST00000896311, ENST00000896312, ENST00000896313, ENST00000896314, ENST00000951076, ENST00001001579, ENST00001001580, ENST00001026057, ENST00001106981, ENST00001106982, ENST00001113618, ENST00001144354

RefSeq mRNA: 6 — MANE Select: NM_019894 NM_001083947, NM_001173551, NM_001173552, NM_001290094, NM_001290096, NM_019894

CCDS: CCDS31684, CCDS44743, CCDS53716, CCDS53717, CCDS76482

Canonical transcript exons

ENST00000437212 — 13 exons

Exon	Start	End
ENSE00001292654	118094816	118094855
ENSE00002096545	118077078	118077305
ENSE00002121417	118098985	118099098
ENSE00002182667	118117902	118121890
ENSE00003509163	118115138	118115280
ENSE00003512276	118111741	118111900
ENSE00003539015	118103101	118103253
ENSE00003585962	118107774	118107875
ENSE00003618968	118104691	118104820
ENSE00003647038	118108856	118108896
ENSE00003652413	118117305	118117454
ENSE00003654765	118113269	118113435
ENSE00003666776	118114829	118114927

Expression profiles

Bgee: expression breadth ubiquitous, 195 present calls, max score 98.96.

FANTOM5 (CAGE): breadth broad, TPM avg 5.1991 / max 483.2150, expressed in 297 samples.

Highest expression (Bgee): mucosa of transverse colon, lower esophagus mucosa, nasal cavity epithelium, palpebral conjunctiva, esophagus mucosa.

Genetic regulation across tissues (GTEx eQTL / sQTL)

TMPRSS4 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 10 tissues and its splicing (sQTL) in 11 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 21 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Esophagus Mucosa	sqtl	0.0e+00	-1.69	11:118094815:A:G
Skin Not Sun Exposed Suprapubic	sqtl	1.5e-102	-1.43	11:118094815:A:G
Skin Sun Exposed Lower leg	sqtl	7.3e-86	-1.30	11:118094815:A:G
Colon Transverse	sqtl	3.8e-59	-1.43	11:118094815:A:G
Stomach	sqtl	2.8e-33	-1.22	11:118094815:A:G
Minor Salivary Gland	sqtl	2.3e-20	-1.53	11:118094815:A:G
Esophagus Mucosa	eqtl	2.9e-18	+0.48	11:118125485:A:G
Skin Sun Exposed Lower leg	eqtl	2.4e-14	+0.23	11:118075631:G:GGTT
Skin Not Sun Exposed Suprapubic	eqtl	3.3e-10	+0.21	11:118075631:G:GGTT
Vagina	sqtl	1.4e-09	-1.24	11:118094815:A:G
Prostate	sqtl	1.6e-06	-0.96	11:118094815:A:G
Small Intestine Terminal Ileum	sqtl	9.8e-06	-1.51	11:118094815:A:G
Thyroid	eqtl	6.6e-05	+0.23	11:118088194:A:G
Lung	eqtl	3.0e-03	+0.15	11:118076739:C:T
Stomach	eqtl	5.4e-03	+0.13	11:118071132:A:C
Esophagus Muscularis	eqtl	9.4e-03	-0.67	11:118398959:A:G
Minor Salivary Gland	eqtl	1.6e-02	+0.55	11:117907214:C:G
Kidney Cortex	sqtl	2.0e-02	+1.50	11:118094815:A:G
Colon Transverse	eqtl	2.1e-02	-0.07	11:118094815:A:G
Testis	sqtl	3.0e-02	-1.08	11:117471957:T:C

FANTOM5 promoters

2 alternative TSS:

Promoter ID	TPM avg	Samples expressed
116965	4.9760	294
116964	0.2231	80

Top tissues by expression

showing 100 of 279 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	98.96	gold quality
lower esophagus mucosa	UBERON:0035834	98.93	gold quality
nasal cavity epithelium	UBERON:0005384	98.57	gold quality
palpebral conjunctiva	UBERON:0001812	97.84	gold quality
esophagus mucosa	UBERON:0002469	97.48	gold quality
rectum	UBERON:0001052	97.31	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	96.54	gold quality
epithelium of nasopharynx	UBERON:0001951	94.86	gold quality
colonic mucosa	UBERON:0000317	94.71	gold quality
esophagus squamous epithelium	UBERON:0006920	94.53	gold quality
gall bladder	UBERON:0002110	94.40	gold quality
epithelium of esophagus	UBERON:0001976	94.27	gold quality
mucosa of sigmoid colon	UBERON:0004993	93.67	gold quality
nasal cavity mucosa	UBERON:0001826	93.49	gold quality
ileal mucosa	UBERON:0000331	91.95	gold quality
colonic epithelium	UBERON:0000397	91.31	gold quality
duodenum	UBERON:0002114	90.83	gold quality
pharyngeal mucosa	UBERON:0000355	90.74	gold quality
squamous epithelium	UBERON:0006914	90.57	gold quality
oral cavity	UBERON:0000167	90.10	gold quality
epithelium of bronchus	UBERON:0002031	89.06	gold quality
pancreatic ductal cell	CL:0002079	88.94	gold quality
transverse colon	UBERON:0001157	88.85	gold quality
mucosa of urinary bladder	UBERON:0001259	88.84	gold quality
bronchus	UBERON:0002185	88.76	gold quality
bronchial epithelial cell	CL:0002328	87.36	gold quality
urinary bladder	UBERON:0001255	87.04	gold quality
gingiva	UBERON:0001828	86.52	gold quality
gingival epithelium	UBERON:0001949	86.51	gold quality
metanephros cortex	UBERON:0010533	86.30	gold quality
small intestine Peyer’s patch	UBERON:0003454	85.22	gold quality
small intestine	UBERON:0002108	85.03	gold quality
tongue squamous epithelium	UBERON:0006919	84.89	silver quality
buccal mucosa cell	CL:0002336	83.77	gold quality
trachea	UBERON:0003126	83.03	gold quality
epithelial cell of pancreas	CL:0000083	82.97	silver quality
tonsil	UBERON:0002372	82.82	gold quality
vagina	UBERON:0000996	81.84	gold quality
type B pancreatic cell	CL:0000169	81.81	gold quality
olfactory bulb	UBERON:0002264	81.71	gold quality
cervix squamous epithelium	UBERON:0006922	81.53	silver quality
jejunal mucosa	UBERON:0000399	81.39	gold quality
intestine	UBERON:0000160	80.78	gold quality
mucosa of paranasal sinus	UBERON:0005030	80.58	gold quality
vermiform appendix	UBERON:0001154	80.32	gold quality
adult mammalian kidney	UBERON:0000082	80.11	gold quality
large intestine	UBERON:0000059	79.21	gold quality
cervix epithelium	UBERON:0004801	79.15	silver quality
caecum	UBERON:0001153	78.60	gold quality
colon	UBERON:0001155	78.52	gold quality
endometrium	UBERON:0001295	78.51	gold quality
male germ cell	CL:0000015	77.64	silver quality
sperm	CL:0000019	77.05	silver quality
mouth mucosa	UBERON:0003729	76.84	gold quality
triceps brachii	UBERON:0001509	76.04	gold quality
minor salivary gland	UBERON:0001830	75.99	gold quality
esophagus	UBERON:0001043	75.49	gold quality
kidney	UBERON:0002113	74.51	gold quality
amniotic fluid	UBERON:0000173	74.39	gold quality
gluteal muscle	UBERON:0002000	73.97	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	72.93	gold quality
body of stomach	UBERON:0001161	72.33	gold quality
stomach	UBERON:0000945	72.20	gold quality
uterine cervix	UBERON:0000002	72.15	gold quality
saliva-secreting gland	UBERON:0001044	72.06	gold quality
urethra	UBERON:0000057	71.93	gold quality
islet of Langerhans	UBERON:0000006	71.87	gold quality
diaphragm	UBERON:0001103	71.74	gold quality
metanephros	UBERON:0000081	71.56	gold quality
jejunum	UBERON:0002115	70.74	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	70.56	gold quality
skin of abdomen	UBERON:0001416	70.19	gold quality
hair follicle	UBERON:0002073	69.07	gold quality
periodontal ligament	UBERON:0008266	69.07	gold quality
tongue	UBERON:0001723	68.60	gold quality
endocervix	UBERON:0000458	68.32	gold quality
superior surface of tongue	UBERON:0007371	68.16	gold quality
cortex of kidney	UBERON:0001225	67.96	gold quality
zone of skin	UBERON:0000014	67.55	gold quality
body of tongue	UBERON:0011876	67.08	gold quality
left testis	UBERON:0004533	66.72	gold quality
thymus	UBERON:0002370	66.37	gold quality
mammalian vulva	UBERON:0000997	66.36	silver quality
skin of leg	UBERON:0001511	66.24	gold quality
uterus	UBERON:0000995	65.95	gold quality
upper arm skin	UBERON:0004263	65.36	gold quality
oviduct epithelium	UBERON:0004804	65.32	silver quality
cauda epididymis	UBERON:0004360	65.01	gold quality
testis	UBERON:0000473	64.96	gold quality
superficial temporal artery	UBERON:0001614	64.81	gold quality
prostate gland	UBERON:0002367	64.61	gold quality
mucosa of stomach	UBERON:0001199	64.57	gold quality
quadriceps femoris	UBERON:0001377	64.51	gold quality
ectocervix	UBERON:0012249	64.18	gold quality
vastus lateralis	UBERON:0001379	63.93	gold quality
fundus of stomach	UBERON:0001160	63.83	gold quality
right testis	UBERON:0004534	63.55	gold quality
fallopian tube	UBERON:0003889	62.82	gold quality
female reproductive system	UBERON:0000474	62.43	gold quality
pylorus	UBERON:0001166	62.38	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-114	yes	61.62
E-MTAB-6386	no	18.05
E-ANND-3	no	0.00

HPA expression

RNA tissue specificity: Tissue enhanced

showing 60 of 155 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Skeletal muscle	tissue	539.5	medium
Tongue	tissue	291.8
Cerebral cortex	tissue	229.0	medium
Somatosensory cortex	tissue	229.0
Prefrontal cortex	tissue	219.6
Occipital cortex	tissue	218.9
Motor cortex	tissue	206.2
Hippocampal formation	tissue	200.7
Entorhinal cortex	tissue	200.7
Temporal cortex	tissue	193.0
Retrosplenial and cingulate cortex	tissue	180.2
Frontal cortex	tissue	173.1
Basal ganglia	tissue	169.6	high
Putamen	tissue	158.6
Caudate putamen	tissue	157.2
Insular cortex	tissue	153.2
Retrosplenial cortex	tissue	151.1
Postcentral gyrus	tissue	144.4
Ventral forebrain	tissue	128.2
Hippocampus	tissue	114.7	high
Heart muscle	tissue	106.3	high
Cerebellum	tissue	90.1	high
Amygdala	tissue	89.5
Septum	tissue	88.5
Urinary bladder	tissue	69.6	medium
Nucleus accumbens	tissue	63.1
Thalamus	tissue	62.8
Midbrain	tissue	53.8
Superior colliculi	tissue	52.4
Locus coeruleus	tissue	45.7
Pons	tissue	45.6
Colon	tissue	40.8	medium
Rectum	tissue	40.3	medium
Smooth muscle	tissue	39.8	medium
Choroid plexus	tissue	38.3
Hypothalamus	tissue	37.4
Substantia nigra	tissue	32.8
Esophagus	tissue	32.3	medium
Medulla oblongata	tissue	30.1
Stomach 1	tissue	29.6	medium
Seminal vesicle	tissue	28.8	not detected
Olfactory bulb	tissue	28.6
Endometrium 1	tissue	26.5	not detected
Spinal cord	tissue	24.0
Duodenum	tissue	23.9	medium
Prostate	tissue	23.5	not detected
Periaqueductal gray	tissue	22.9
Small intestine	tissue	21.1	medium
Esophagus	tissue	20.4	not detected
Corpus callosum	tissue	19.9
Epididymis	tissue	16.8	not detected
Adipose tissue	tissue	16.7	not detected
Fallopian tube	tissue	15.8	not detected
Vagina	tissue	15.7	medium
Cervix	tissue	15.6
Cervix	tissue	14.4	not detected
Tonsil	tissue	14.0	medium
Gallbladder	tissue	13.4	medium
Urinary bladder	tissue	13.2	not detected
Adrenal gland	tissue	10.9	low

Brain sub-regions (HPA Brain Atlas): detected in 380; highest nTPM — Dorsal hippocampus (185.5), Posterior cingulate cortex (165.3), Hippocampus, CA1 (149.6), Hippocampus, CA3 (146.4), Ventral hippocampus (139.2).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting TMPRSS4 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 71 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-6844	99.82	70.69	2423
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-4799-5P	99.82	70.60	2663
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-378G	99.71	64.90	1106
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-6512-3P	99.65	66.07	1468
HSA-MIR-6720-5P	99.65	66.22	1459
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-4677-3P	99.49	67.91	1246
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-122B-5P	99.46	70.81	1457
HSA-MIR-3915	99.45	68.49	1905
HSA-MIR-4796-5P	99.34	70.06	810
HSA-MIR-664A-3P	99.22	71.08	2696

Functional genomics

gnomAD constraint: pLI 6.81e-11, LOEUF 0.94, missense Z 0.561 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000437212 — one region, missense o/e 0.98.

Literature-anchored findings (GeneRIF, showing 40)

• TMPRSS4 plays a role in invasion, metastasis, migration and adhesion in cancer cells. TMPRSS4 may contribute to tumor cell invasion and metastasis by promoting an epithelial-mesenchymal transition(EMT) through the strong SIP1/ZEB2 induction. (PMID:17968309)
• The authors provide evidence that TMPRSS2 and TMPRSS4 activate the 1918 HA by cleavage and therefore may promote viral spread in lung tissue. (PMID:19158246)
• TMPRSS4 expression was significantly higher in human colorectal cancer tissues from advanced stages than in that of early stage. (PMID:20118200)
• RNAi-mediated knockdown of TMPRSS2 and TMPRSS4 in Caco-2 cells, which released fully infectious virus without trypsin treatment, markedly reduced the spread of influenza virus, demonstrating that these proteases were responsible for activation of HA. (PMID:20631123)
• Overexpression of TMPRSS4 has a critical role in radiation-induced long-term dissemination and metastasis of residual HCC by facilitating EMT. (PMID:21637307)
• Kaplan-Meier curves demonstrated that high levels of TMPRSS4 were significantly associated (P=0.017) with reduced overall survival in the patients with SCC histology, whereas no correlation was found for the AC histology (PMID:22067904)
• results demonstrate overexpression of TMPRSS4 in non-small cell lung carcinoma at both the mRNA and protein levels. In addition, our findings suggest that expression of TMPRSS4 in the tumor microenvironment is regulated by hypoxia. (PMID:22692880)
• Progression and metastatic potential of several cancers is concordant with an increased expression of TMPRSS4. (PMID:22944691)
• TMPRSS4 expression is a putative biological marker for breast cancer and is an indicator of poor prognosis. (PMID:23420063)
• Expression of TMPRSS4 in gastric cancer is significantly associated with lymph node and distant metastasis, high Erk1 expression, and poor prognosis. (PMID:23922976)
• A mutation in the serine protease TMPRSS4 in a novel pediatric neurodegenerative disorder (PMID:23957953)
• TMPRSS4 induced the transcription of uPA gene through activating the transcription factors Sp1, Sp3, and AP-1 in a JNK-dependent manner and that the induction of uPA was required for TMPRSS4-mediated cancer cell invasion. (PMID:23978400)
• High TMPRSS4 expression is associated with cervical squamous cell carcinoma. (PMID:24012692)
• High expression of TMPRSS4 was significantly associated with advanced TNM stage. (PMID:24072509)
• TMPRSS4 was an independent predictor of OS and DFS. (PMID:24132607)
• Our data suggest that TMPRSS4 positivity is associated with GC invasion and lymph node metastasis. We propose TMPRSS4 expression as an indicator of poor prognosis in GC patients (PMID:24299317)
• TMPRSS4 was associated with CRC stage and regulated the proliferation and self-renewal ability of colon cancer cells; TMRPSS4 was involved in the development and progression of CRC. (PMID:24335200)
• TMPRSS4 directly converted inactive pro-uPA into the active form through its proteolytic activity. Conditioned medium from cells overexpressing TMPRSS4 showed that the active TMPRSS4 protease domain is released and is associated with the plasma membrane. (PMID:24434139)
• We have demonstrated for the first time a new molecular pathway that connects TMPRSS4 and integrin alpha5 through miR-205 to regulate cancer cell invasion and metastasis (PMID:24434435)
• increased TMPRSS4 expression was an independent predictor of poor prognosis for overall survival in gallbladder cancer. patients. (PMID:24532432)
• On the basis of this information and the structural characteristics of this druggable protease, we suggest that TMPRSS4 could be a novel potential therapeutic target in solid tumours. (PMID:25203520)
• TMPRSS4 is overexpressed in thyroid cancer and TMPRSS4-CREB signaling is needed to sustain thyroid cancer cell proliferation. (PMID:25244400)
• TMPRSS4 is upregulated by silencing of TFPI-2 through aberrant DNA methylation and contributes to oncogenesis in non-small cell lung cancer. (PMID:25414083)
• In prostate cancer, high TMPRSS4 expression was significantly associated with advanced tumor stage and lymphatic metastasis. (PMID:25550850)
• The increase of TMPRSS4 expression may be a key event for HCC progression and may be regarded as a potential prognostic marker for HCC. (PMID:26190376)
• suggesting that TMPRSS4 is associated with a cancer stem cells phenotype in patients’ tumors (PMID:26546046)
• TMPRSS4 expression is associated with postoperative recurrence. In addition, the current survival curves demonstrated that TMPRSS4 expression is associated with statistically significant differences in survival among patients with lung adenocarcinoma. (PMID:26722035)
• TMPRSS4 is a novel independent prognostic biomarker regulated by epigenetic changes in lung squamous cell carcinomas (PMID:26989022)
• High TMPRSS4 expression is associated with pancreatic adenocarcinoma. (PMID:26993610)
• We conclude that TMPRSS4 overexpression in solid tumors is associated with patients’ poor prognosis. TMPRSS4 could be a valuable prognosis biomarker or a promising therapeutic target of solid tumor. (PMID:27344186)
• TMPRSS4 modulates both invasion and proliferation via Slug and cyclin D1, which is a previously unrecognized pathway that may regulate metastasis and cancer progression (PMID:27385093)
• TMPRSS4 overexpression promoted the proliferation, invasion and migration of breast cancer cells by possibly inducing epithelial-mesenchymal transition (PMID:28259959)
• we demonstrated a mechanistic cascade of TMPRSS4 up-regulating STAT3 activation and subsequent TWIST1 expression, leading to prostate cancer migration. (PMID:28466252)
• These results revealed that CLDN1 contributed to cancer stem cell features of hepatocellular carcinoma, which was altered by TMPRSS4 expression via ERK1/2 signaling pathway, providing promising targets for novel specific therapies. (PMID:28651932)
• TMPRSS4 protein expression in esophageal carcinoma was correlated with patient demographic characteristics, tumor type, high TNM stages and overall survival. (PMID:29254316)
• Data suggest that miR-551b-3p functions as a tumour suppressor gene in gastric cancer, and its function is regulated by long noncoding RNAs (lncRNAs) SMARCC2/miR-551b-3p/transmembrane protease, serine 4 protein (TMPRSS4) axis. (PMID:29337109)
• TMPRSS4 is overexpressed in Idiopathic pulmonary fibrosis lungs. (PMID:29529050)
• The miR125a5p/TMPRSS4/NFkappaB axis may thus provide novel insight into the pathogenic mechanisms of lung adenocarcinoma and may be used in the development of novel treatment strategies for lung adenocarcinoma . (PMID:29750426)
• The authors demonstrated that TMPRSS4 expression was significantly upregulated in fine needle aspiration biopsy specimens from Papillary thyroid cancer patients compared with benign nodules, and appeared to be a helpful diagnostic marker for distinguishing malignant from benign nodules. (PMID:30518486)
• TMPRSS4 silencing in breast cancer reduces cells proliferation by promoting cell cycle arrest (PMID:31244309)

Cross-species orthologs

14 orthologs

Organism	Symbol	Gene ID
danio_rerio	hp	ENSDARG00000051890
mus_musculus	Tmprss4	ENSMUSG00000032091
rattus_norvegicus	Tmprss4	ENSRNOG00000026650
drosophila_melanogaster	CG9673	FBGN0030775
drosophila_melanogaster	CG4477	FBGN0035971
drosophila_melanogaster	CG17404	FBGN0038001
drosophila_melanogaster	CG12256	FBGN0038002
drosophila_melanogaster	CG3916	FBGN0038003
drosophila_melanogaster	CG17477	FBGN0038479
drosophila_melanogaster	CG4053	FBGN0038482
drosophila_melanogaster	CG31269	FBGN0051269
drosophila_melanogaster	CG32808	FBGN0052808
drosophila_melanogaster	Phae2	FBGN0263235
drosophila_melanogaster	Send2	FBGN0264253

Paralogs (12): PRSS54 (ENSG00000103023), KLK14 (ENSG00000129437), KLK8 (ENSG00000129455), KLK3 (ENSG00000142515), KLK1 (ENSG00000167748), KLK4 (ENSG00000167749), KLK2 (ENSG00000167751), KLK5 (ENSG00000167754), KLK11 (ENSG00000167757), KLK7 (ENSG00000169035), KLK12 (ENSG00000186474), PRSS58 (ENSG00000258223)

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Phytophthora sojae strain P6497	G5AE35	100.0%	Diamond
Phytophthora sojae	Q945T8	100.0%	Diamond
Pongo abelii	Q5R5E8	99.3%	Diamond
Pan troglodytes	Q5G271	99.2%	Diamond
Nomascus leucogenys	Q5G268	98.5%	Diamond
Gorilla gorilla gorilla	Q5G270	98.5%	Diamond
Trachypithecus phayrei	Q5G266	98.3%	Diamond
Macaca mulatta	Q5G267	98.3%	Diamond
Pongo pygmaeus	Q5G269	96.7%	Diamond
Manduca sexta	P35045	96.1%	Diamond
Saguinus labiatus	Q5G265	95.5%	Diamond
Drosophila erecta	P54627	94.9%	Diamond
Capra hircus	Q28315	92.7%	Diamond
Canis lupus familiaris	P04813	87.1%	Diamond
Bos taurus	P98072	85.9%	Diamond
Sus scrofa	P98074	85.9%	Diamond
Mesocricetus auratus	P15156	84.7%	Diamond
Streptomyces exfoliatus	P80420	82.7%	Diamond
Euroglyphus maynei	O97370	82.3%	Diamond
Dermatophagoides farinae	P49275	82.3%	Diamond
Dermatophagoides pteronyssinus	P39675	81.6%	Diamond
Streptomyces griseus	P00775	81.1%	Diamond
Lonomia achelous	P23604	79.4%	Diamond
Anopheles gambiae	P35035	78.3%	Diamond
Oryctolagus cuniculus	P48038	76.7%	Diamond
Ovis aries	Q9GL10	76.5%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
IL10RA	protein-coding	3587
SCN4B	protein-coding	6330
TMPRSS13	protein-coding	84000
SMIM35	protein-coding	100526771
SCN2B	protein-coding	6327
JAML	protein-coding	120425
FXYD6-FXYD2	protein-coding	100533181
FXYD6-AS1	ncRNA	123706543
FXYD6	protein-coding	53826
MPZL3	protein-coding	196264

Protein

Protein identifiers

Transmembrane protease serine 4 — Q9NRS4 (reviewed: Q9NRS4)

Alternative names: Channel-activating protease 2, Membrane-type serine protease 2

All UniProt accessions (10): Q9NRS4, A0A087WTU6, A0AAQ5BHV3, A0AAQ5BHV4, E5RIH1, E5RJR8, E7ESG9, G3V124, H0YAX8, H0YBM5

UniProt curated annotations — full annotation on UniProt →

Function. Plasma membrane-anchored serine protease that directly induces processing of pro-uPA/PLAU into the active form through proteolytic activity. Seems to be capable of activating ENaC. (Microbial infection) In gut epithelial cells, facilitates human coronavirus SARS-CoV-2 infection through, at least, the cleavage of coronavirus spike glycoproteins which activates the glycoprotein for host cell entry.

Subcellular location. Cell membrane Secreted.

Tissue specificity. High levels in pancreatic, gastric, colorectal and ampullary cancer. Very weak expression in normal gastrointestinal and urogenital tract. Coexpressed with ACE2 within mature enterocytes.

Post-translational modifications. Proteolytically processed; probably by an autocatalytic mechanism.

Similarity. Belongs to the peptidase S1 family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q9NRS4-1	1	yes
Q9NRS4-2	2
Q9NRS4-3	3
Q9NRS4-4	4

RefSeq proteins (6): NP_001077416, NP_001167022, NP_001167023, NP_001277023, NP_001277025, NP_063947* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001190	SRCR	Domain
IPR001254	Trypsin_dom	Domain
IPR001314	Peptidase_S1A	Family
IPR002172	LDrepeatLR_classA_rpt	Repeat
IPR009003	Peptidase_S1_PA	Homologous_superfamily
IPR018114	TRYPSIN_HIS	Active_site
IPR033116	TRYPSIN_SER	Active_site
IPR036055	LDL_receptor-like_sf	Homologous_superfamily
IPR036772	SRCR-like_dom_sf	Homologous_superfamily
IPR043504

Pfam: PF00089, PF15494

UniProt features (31 total): disulfide bond 8, active site 3, splice variant 3, sequence variant 3, domain 3, chain 2, glycosylation site 2, topological domain 2, mutagenesis site 2, site 1, transmembrane region 1, sequence conflict 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NRS4-F1	88.01	0.67

Human Protein Atlas

Protein class: Predicted intracellular proteins, Cancer-related genes, Mutated cancer genes

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): cytosol; nucleoplasm; plasma membrane

Antibody reliability (HPA): IH enhanced · IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (4)

Position	Role
387	charge relay system
204–205	cleavage
245	charge relay system
290	charge relay system

Disulfide bonds (8)

Type	Positions
Disulfide bond	64–83, 77–92, 127–183, 140–193, 196–310, 230–246, 356–372, 383–410

Glycosylation sites (2)

Type	Positions
N-linked (glcnac…) asparagine	130, 178

Mutagenesis-validated functional residues (2)

Position	Phenotype
290	abolishes protease activity.
387	abolishes protease activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

MSigDB gene sets: 449 (showing top): WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN, TGGTGCT_MIR29A_MIR29B_MIR29C, MODULE_52, YAGI_AML_WITH_INV_16_TRANSLOCATION, GOBP_ESTABLISHMENT_OR_MAINTENANCE_OF_CELL_POLARITY, GOBP_SENSORY_PERCEPTION_OF_MECHANICAL_STIMULUS, GOCC_SECRETORY_GRANULE, BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_DN, GOZGIT_ESR1_TARGETS_DN, ASTON_MAJOR_DEPRESSIVE_DISORDER_DN, GOBP_GROWTH, GOBP_POSITIVE_REGULATION_OF_LYASE_ACTIVITY, FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_DN, PATIL_LIVER_CANCER, SENESE_HDAC1_AND_HDAC2_TARGETS_DN

GO Biological Process (5): proteolysis (GO:0006508), regulation of gene expression (GO:0010468), protein processing (GO:0016485), negative regulation of growth rate (GO:0045967), positive regulation of viral entry into host cell (GO:0046598)

GO Molecular Function (5): serine-type endopeptidase activity (GO:0004252), serine-type peptidase activity (GO:0008236), protein binding (GO:0005515), peptidase activity (GO:0008233), hydrolase activity (GO:0016787)

GO Cellular Component (6): plasma membrane (GO:0005886), membrane (GO:0016020), secretory granule (GO:0030141), extracellular region (GO:0005576), cytoplasm (GO:0005737), endomembrane system (GO:0012505)

GO top-level categories

27 GO namespaces:

Category	Terms
cellular anatomical structure	4
protein metabolic process	1
gene expression	1
regulation of macromolecule biosynthetic process	1
proteolysis	1
protein maturation	1
regulation of growth rate	1
negative regulation of growth	1
regulation of viral entry into host cell	1
symbiont entry into host cell	1
positive regulation by symbiont of entry into host	1
positive regulation of viral life cycle	1
endopeptidase activity	1
serine-type peptidase activity	1
peptidase activity	1
serine hydrolase activity	1
binding	1
hydrolase activity	1
catalytic activity, acting on a protein	1
catalytic activity	1
membrane	1
cell periphery	1
endomembrane system	1
secretory vesicle	1
intracellular anatomical structure	1
vacuole	1
plasma membrane	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 7 of 17 annotations. The rest are phylogenetic / computational / electronic (IEA).

7 experimentally-supported GO terms:

GO term	NS	Evidence
negative regulation of growth rate	BP	direct assay
positive regulation of viral entry into host cell	BP	direct assay
protein processing	BP	direct assay
proteolysis	BP	direct assay
regulation of gene expression	BP	direct assay
secretory granule	CC	direct assay
serine-type peptidase activity	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 978 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMPRSS4	ACE2	Q9BYF1	717
TMPRSS4	MYO15A	Q9UKN7	700
TMPRSS4	FURIN	P09958	683
TMPRSS4	TMC1	Q8TDI8	677
TMPRSS4	OTOF	Q9HC10	653
TMPRSS4	SLC26A4	O43511	652
TMPRSS4	GJB2	P29033	651
TMPRSS4	CDH23	Q9H251	621
TMPRSS4	ZFYVE9	O95405	618
TMPRSS4	CTSL	P07711	602
TMPRSS4	OTOA	Q7RTW8	592
TMPRSS4	LOXHD1	Q8IVV2	579
TMPRSS4	MYO7A	P78427	571
TMPRSS4	STRC	Q7RTU9	571
TMPRSS4	CTSS	P25774	559

IntAct

Human interaction partners of TMPRSS4 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

12 partners by confidence:

Partner	Interaction type	MIscore	Records
BNIP3L	physical association	0.560	3
CLRN1	physical association	0.560	3
CSNK1D	physical association	0.560	3
ERVFRD-1	physical association	0.560	3
FAM209A	physical association	0.560	3
FNDC9	physical association	0.560	3
GPX8	physical association	0.560	3
KASH5	physical association	0.560	3
RASGRP4	physical association	0.560	3
SIGLEC12	physical association	0.560	3
SUSD3	physical association	0.560	3
TMEM79	physical association	0.560	3

BioGRID (371 interactions; top human partners by supporting records): MET (Affinity Capture-MS; 3 records), ADAM15 (Affinity Capture-MS; 2 records), AFG3L2 (Affinity Capture-MS; 2 records), AIF1L (Affinity Capture-MS; 2 records), APP (Affinity Capture-MS; 2 records), ATP1B3 (Affinity Capture-MS; 2 records), AUP1 (Affinity Capture-MS; 2 records), B4GAT1 (Affinity Capture-MS; 2 records), BSG (Affinity Capture-MS; 2 records), C19orf70 (Affinity Capture-MS; 2 records), CDH2 (Affinity Capture-MS; 2 records), CHPF2 (Affinity Capture-MS; 2 records), CLGN (Affinity Capture-MS; 2 records), CNNM4 (Affinity Capture-MS; 2 records), COCH (Affinity Capture-MS; 2 records)

SIGNOR signaling

showing 1 of 2 signaling interactions:

A	Effect	B	Mechanism
TMPRSS4	“up-regulates activity”	S	cleavage

Disease & clinical

Genetic variants

Variant evidence for TMPRSS4: 178 ClinVar records (4 pathogenic / likely pathogenic); 5 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

178 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	1
Uncertain significance	131
Likely benign	12
Benign	1

Top pathogenic / likely-pathogenic (4)

Showing all 4 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
4845338	NM_006366.3(CAP2):c.870del (p.Ser291fs)	Likely pathogenic	criteria provided, single submitter	1
2574649	NM_006366.3(CAP2):c.636+1G>A	Pathogenic	no assertion criteria provided	1
2574650	NM_006366.3(CAP2):c.948T>G (p.Tyr316Ter)	Pathogenic	no assertion criteria provided	1
2574651	NM_006366.3(CAP2):c.1288del (p.Cys430fs)	Pathogenic	no assertion criteria provided	1

Per-variant reference — Sugi Variant

Explore TMPRSS4’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 31 predictions of 2,546):

Position(s)	Effect	Δscore	Sites
11:118091957	donor_gain	1.0000
11:118103089	acceptor_gain	1.0000
11:118103254–118103255	donor_loss	1.0000	5
11:118104689–118104690	acceptor_loss	1.0000	6
11:118104821–118104822	donor_loss	1.0000	4
11:118107762	acceptor_gain	1.0000
11:118111901–118111902	donor_loss	1.0000	5
11:118113436–118113437	donor_loss	1.0000	5
6:17393747–17393748	donor_loss	1.0000	2
6:17507613	acceptor_gain	1.0000

AlphaMissense

465 missense substitutions predicted likely pathogenic (of 2,884 scored), across 136 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
D88	8	0.806	0.933
M370	8	0.685	0.825
C83	7	0.946	0.977
C77	7	0.943	0.983
C64	7	0.906	0.956
C92	7	0.902	0.945
C140	7	0.890	0.934
W428	7	0.888	0.976
W218	7	0.883	0.969
C193	7	0.880	0.932
C356	7	0.880	0.953
C127	7	0.874	0.922
C310	7	0.873	0.917
C372	7	0.865	0.946
C183	7	0.851	0.903
C246	7	0.844	0.902
W329	7	0.841	0.949
W256	7	0.821	0.941
C230	7	0.809	0.880
W239	7	0.788	0.919

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

3 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	7.39e-06
Pancreatic Adenocarcinoma (TCGA)	unfavorable	0.000137
Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA)	favorable	0.000726

Disease associations

OMIM: gene MIM:606565 | disease phenotypes: MIM:620462

GenCC curated gene-disease

3 curated gene-disease records:

Disease	Classification	Inheritance	Records
cardiomyopathy, dilated, 2I	Moderate	Autosomal recessive
autosomal recessive cerebral atrophy	Supportive	Autosomal recessive
familial isolated dilated cardiomyopathy	Supportive	Autosomal dominant

Mondo (3): cardiomyopathy, dilated, 2I (MONDO:0957545), autosomal recessive cerebral atrophy (MONDO:0018218), (MONDO:0015470)

HPO phenotypes

18 phenotypes (HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000407	Sensorineural hearing impairment
HP:0000969	Edema
HP:0001635	Congestive heart failure
HP:0001644	Dilated cardiomyopathy
HP:0001727	Thromboembolic stroke
HP:0002875	Exertional dyspnea
HP:0003198	Myopathy
HP:0003457	EMG abnormality
HP:0003621	Juvenile onset
HP:0004755	Supraventricular tachycardia
HP:0011463	Childhood onset
HP:0011675	Arrhythmia
HP:0012378	Fatigue
HP:0012666	Severely reduced left ventricular ejection fraction
HP:0012764	Orthopnea
HP:0025169	Left ventricular systolic dysfunction
HP:0100578	Lipoatrophy

GWAS associations

5 associations:

Study	Trait	p-value
GCST90014033_97	Haemorrhoidal disease	2e-12
GCST005171_43	QT interval	3e-7
GCST000175_16	Height	7e-7
GCST002616_3	Mitochondrial DNA levels	2e-6
GCST002868_6	Response to serotonin reuptake inhibitors in major depressive disorder	2e-6

EFO canonical traits (from GWAS)

3 canonical traits:

EFO ID	Trait name
EFO:0006312	mitochondrial DNA measurement
EFO:0005658	response to selective serotonin reuptake inhibitor
EFO:0004682	QT interval

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2331048 (SINGLE PROTEIN), CHEMBL4742321 (PROTEIN-PROTEIN INTERACTION)

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 482 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

1 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL536151	IMD-0354	1	482

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

30 measured of 41 human assays (41 total across all organisms); most potent 30 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL2179173	IC50	29 nM
CHEMBL2088014	IC50	38 nM
CHEMBL2338695	IC50	58 nM
CHEMBL461542	IC50	77 nM
MMV665807	IC50	91 nM
CHEMBL2313115	IC50	236 nM
TCMDC-125465	IC50	250 nM
CHEMBL2178702	IC50	323 nM
CHEMBL2338686	IC50	341 nM
CHEMBL2313119	IC50	755 nM
CHEMBL2338696	IC50	1140 nM
CHEMBL2313134	IC50	1530 nM
CHEMBL2313116	IC50	1660 nM
CHEMBL2313122	IC50	2530 nM
CHEMBL2338685	IC50	6000 nM
CHEMBL2313097	IC50	10000 nM
CHEMBL2338684	IC50	12000 nM
CHEMBL2338683	IC50	12000 nM
CHEMBL2313117	IC50	13000 nM
CHEMBL2313136	IC50	13000 nM
CHEMBL2313095	IC50	16000 nM
CHEMBL2338697	IC50	19000 nM
CHEMBL2313138	IC50	20000 nM
CHEMBL2313080	IC50	28000 nM
CHEMBL2313089	IC50	30000 nM
CHEMBL2313088	IC50	35000 nM
CHEMBL1892375	IC50	50000 nM
CHEMBL2338689	IC50	80000 nM
CHEMBL2338694	IC50	85000 nM
CHEMBL1256178	IC50	250000 nM

ChEMBL bioactivities

2 potent at pChembl≥5 of 29 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.22	IC50	6000	nM	CHEMBL2338685
5.00	IC50	1e+04	nM	CHEMBL2313097

PubChem BioAssay actives

2 with measured affinity, of 47 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-[4-bromo-3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide	730377: Inhibition of N-terminal His6-tagged recombinant TMPRSS4 (unknown origin) fused with enterokinase cleavage sequence DYKDDDGDYKDDDDK expressed in Escherichia coli BL21 (DE3) using Z-Phe-Arg-7-amido-4-methylcoumarin hydrochloride as substrate by fluorometric analysis	ic50	6.0000	uM
5-chloro-2-hydroxy-N-[4-methyl-3,5-bis(trifluoromethyl)phenyl]benzamide	730377: Inhibition of N-terminal His6-tagged recombinant TMPRSS4 (unknown origin) fused with enterokinase cleavage sequence DYKDDDGDYKDDDDK expressed in Escherichia coli BL21 (DE3) using Z-Phe-Arg-7-amido-4-methylcoumarin hydrochloride as substrate by fluorometric analysis	ic50	10.0000	uM

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	decreases expression, affects cotreatment, increases expression	3
Particulate Matter	increases abundance, increases expression	2
beta-lapachone	increases expression	1
butyraldehyde	increases expression	1
fipronil	increases expression	1
CGP 52608	affects binding, increases reaction	1
rofecoxib	increases expression	1
pinostrobin	increases phosphorylation	1
prothioconazole	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Ethinyl Estradiol	affects expression	1
Ibuprofen	affects expression	1
Nickel	increases expression	1
Tetrachlorodibenzodioxin	affects cotreatment, increases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	increases expression	1
Valproic Acid	increases expression	1
Okadaic Acid	increases expression	1
Genistein	affects expression	1

ChEMBL screening assays

21 unique, capped per target: 21 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2343322	Binding	Inhibition of TMPRSS4 in human SW480 cells assessed as inhibition of cell invasion at 0.1 uM relative to control	Discovery of novel 2-hydroxydiarylamide derivatives as TMPRSS4 inhibitors. — *Bioorg Med Chem Lett*

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for TMPRSS4 across ~30M SureChEMBL compounds — explore on Sugi Predict.